# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Oren Livnat maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price targ...
ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per s...
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("...
U.S. annual sales for Sodium Polystyrene Sulfonate Oral / Rectal Suspension total approximately $30.3 million, based on March 2...
HC Wainwright & Co. analyst Oren Livnat maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price targ...
ANI continues to expect total company adjusted non-GAAP gross margin between 62% and 63% and the Company will continue to tax e...